Senseonics (SENS) Competitors

$0.42
0.00 (0.00%)
(As of 04/26/2024 ET)

SENS vs. MLAB, PRLD, MACK, GTHX, FHTX, ARAY, ACRV, PSTX, IMMP, and DSGN

Should you be buying Senseonics stock or one of its competitors? The main competitors of Senseonics include Mesa Laboratories (MLAB), Prelude Therapeutics (PRLD), Merrimack Pharmaceuticals (MACK), G1 Therapeutics (GTHX), Foghorn Therapeutics (FHTX), Accuray (ARAY), Acrivon Therapeutics (ACRV), Poseida Therapeutics (PSTX), Immutep (IMMP), and Design Therapeutics (DSGN). These companies are all part of the "medical" sector.

Senseonics vs.

Senseonics (NYSE:SENS) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.

Mesa Laboratories has a net margin of 0.45% compared to Senseonics' net margin of -270.13%. Mesa Laboratories' return on equity of 7.41% beat Senseonics' return on equity.

Company Net Margins Return on Equity Return on Assets
Senseonics-270.13% -146.90% -49.81%
Mesa Laboratories 0.45%7.41%4.34%

Senseonics currently has a consensus target price of $1.25, suggesting a potential upside of 200.70%. Mesa Laboratories has a consensus target price of $130.00, suggesting a potential upside of 25.98%. Given Senseonics' higher possible upside, equities analysts clearly believe Senseonics is more favorable than Mesa Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senseonics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Mesa Laboratories
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Senseonics and Senseonics both had 1 articles in the media. Mesa Laboratories' average media sentiment score of 1.00 beat Senseonics' score of 0.00 indicating that Mesa Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
Senseonics Neutral
Mesa Laboratories Positive

Mesa Laboratories has higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Senseonics$22.39M9.86-$60.39M-$0.11-3.78
Mesa Laboratories$219.08M2.54$930K$0.17607.04

Mesa Laboratories received 216 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 63.82% of users gave Mesa Laboratories an outperform vote while only 25.00% of users gave Senseonics an outperform vote.

CompanyUnderperformOutperform
SenseonicsOutperform Votes
1
25.00%
Underperform Votes
3
75.00%
Mesa LaboratoriesOutperform Votes
217
63.82%
Underperform Votes
123
36.18%

Senseonics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Mesa Laboratories has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

12.4% of Senseonics shares are held by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are held by institutional investors. 3.9% of Senseonics shares are held by company insiders. Comparatively, 5.2% of Mesa Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Mesa Laboratories beats Senseonics on 13 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SENS vs. The Competition

MetricSenseonicsProcess control instruments IndustryMedical SectorNYSE Exchange
Market Cap$220.66M$20.84B$4.88B$17.47B
Dividend YieldN/A1.01%2.91%3.55%
P/E Ratio-3.7878.22232.4825.14
Price / Sales9.864.502,338.7010.49
Price / CashN/A16.9447.0417.65
Price / Book5.943.204.764.87
Net Income-$60.39M$474.99M$103.54M$964.96M
7 Day Performance4.13%-0.35%0.74%1.90%
1 Month Performance-26.24%-8.81%-7.60%-3.08%
1 Year PerformanceN/A17.73%9.25%96.69%

Senseonics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MLAB
Mesa Laboratories
3.8257 of 5 stars
$102.26
+1.5%
$130.00
+27.1%
-37.6%$551.18M$219.08M601.56698Short Interest ↓
Positive News
PRLD
Prelude Therapeutics
2.5225 of 5 stars
$3.85
+3.5%
$5.25
+36.4%
-29.2%$211.44MN/A-1.89128
MACK
Merrimack Pharmaceuticals
0 of 5 stars
$14.73
+0.1%
N/A+19.6%$214.03MN/A-184.13426Upcoming Earnings
GTHX
G1 Therapeutics
4.1057 of 5 stars
$4.10
-0.2%
$9.33
+127.6%
+47.8%$214.14M$82.51M-4.32100Upcoming Earnings
Short Interest ↓
Positive News
FHTX
Foghorn Therapeutics
1.4374 of 5 stars
$5.05
-4.7%
$15.40
+205.0%
-13.7%$214.98M$34.15M-2.16116Gap Up
ARAY
Accuray
3.0641 of 5 stars
$2.17
+1.4%
$8.25
+280.2%
-30.9%$215.20M$447.61M-14.471,024Upcoming Earnings
News Coverage
High Trading Volume
ACRV
Acrivon Therapeutics
3.9862 of 5 stars
$9.51
+1.3%
$20.14
+111.8%
-31.2%$215.31MN/A-3.4858Analyst Report
News Coverage
Gap Down
PSTX
Poseida Therapeutics
3.6016 of 5 stars
$2.16
+6.4%
$14.67
+580.6%
-11.6%$207.94M$64.70M-1.55330Gap Down
IMMP
Immutep
1.0845 of 5 stars
$2.32
+3.1%
$8.50
+266.4%
+60.6%$204.00M$3.50M0.002,021News Coverage
DSGN
Design Therapeutics
2.0702 of 5 stars
$3.89
+5.1%
$5.50
+41.4%
-41.6%$219.76MN/A-3.2458Short Interest ↑

Related Companies and Tools

This page (NYSE:SENS) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners